Search the Newsreel

BIIB Upgraded by Wolfe Research -- Price Target Raised to $300

Wolfe Research has upgraded Biogen (BIIB) to "Outperform" and raised its price target to $300.00, reflecting increased confidence in the company's future. Despite this positive sentiment, GuruFocus considers the stock 8.2% overvalued with a GF Value™ of $194.85, and insider activity shows net selling. …

Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation

Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the …

Wolfe Upgrades Biogen to Outperform From Peer Perform, Price Target is $300

Wolfe Research has upgraded Biogen (BIIB) to an "Outperform" rating from "Peer Perform," setting a new price target of $300. This upgrade indicates a positive outlook from the firm regarding Biogen's future stock performance. The report was published on August 13, 2026, at 07:40 …

Handelsbanken Fonder AB Has $20.14 Million Stock Holdings in Biogen Inc. $BIIB

Handelsbanken Fonder AB increased its stake in Biogen Inc. (NASDAQ:BIIB) by 12.7% during the second quarter, bringing its total holdings to 93,236 shares valued at $20.14 million. Institutional investors collectively own 87.93% of Biogen, which has received a consensus "Moderate Buy" rating from analysts …

Biogen Inc. stock outperforms competitors on strong trading day

Shares of Biogen Inc. (BIIB) rose 2.44% to $208.87 on Wednesday, outperforming the mixed market performance. This gain snapped a two-day losing streak for the company's stock. The S&P 500 Index saw a 0.26% increase, while the Dow Jones Industrial Average dropped 0.04%.

BIIB Stock Price Prediction 2025-2026 | Biogen Inc Forecast

Formation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’

Formation Bio has appointed Dr. Michael Ehlers, a former Biogen and Pfizer executive, as its new chief scientific officer and head of R&D. The company aims to leverage AI to optimize the often-overlooked "boring middle" of drug development, such as trial enrollment and site …

Insight Wealth Strategies LLC Has $7.20 Million Holdings in Biogen Inc. $BIIB

Insight Wealth Strategies LLC significantly increased its stake in Biogen Inc. by 16.9% in the second quarter, now holding 34,320 shares valued at $7.20 million. This comes as Biogen reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, with revenue growing …

Biogen Inc. stock underperforms Tuesday when compared to competitors

Shares of Biogen Inc. (BIIB) fell 1.56% to $203.89 on Tuesday, underperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines. This marked the second consecutive day of losses for Biogen's stock.

aTyr, Biogen, City name legal chiefs

Several biopharma companies, including aTyr Pharma, Biogen, City Therapeutics, CytomX Therapeutics, and Sanofi, have recently appointed new chief legal officers or general counsels. These appointments reflect a focus on bolstering legal and compliance functions as these companies advance their therapeutic programs and expand their …

Biogen Inc (BIIB) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

HSBC Adjusts Price Target on Biogen to $165 From $157, Keeps Reduce Rating

HSBC has revised its price target for Biogen Inc. (BIIB) to $165, up from $157, while maintaining a "Reduce" rating on the stock. This adjustment comes amidst other analyst updates for Biogen, including recent price target changes from Mizuho, BMO Capital, TD Cowen, Canaccord …

Should Biogen’s Profit Squeeze Amid Rising New-Therapy Sales Prompt Action From Biogen (BIIB) Investors?

Biogen (BIIB) reported increased revenue in Q2 2026, driven by new therapies and the Apellis acquisition, but experienced a significant drop in net income and diluted EPS. This profit squeeze highlights challenges in offsetting the decline of its legacy multiple sclerosis portfolio with new …

Biogen Inc. (BIIB) Options Chain

This article provides the options chain data for Biogen Inc. (BIIB), including calls and puts that are in the money for the August 28, 2026 expiry. It lists detailed information such as strike prices, last trade dates, last prices, bid/ask spreads, volume, open interest, …

Is Biogen (BIIB) Fully Priced After Earnings Raised Revenue But Cut Profit?

Biogen (BIIB) recently reported Q2 2026 earnings with higher sales but lower net income, raising questions about its current valuation. Despite a 61.47% shareholder return over the past year, the stock is considered 9.4% undervalued by analysts based on long-term growth for its Alzheimer's …

Biogen, Investors Reach Settlement Outline Over Alzheimer’s Drug

Biogen has reached a preliminary settlement agreement with investors who filed a class-action lawsuit alleging the company misrepresented clinical trial data for its Alzheimer's drug, Aduhelm. The terms of the settlement, including the financial amount, are not yet public but are expected to be …

Biogen closes deal for USD 1b buyout of RayThera

Biogen has completed its acquisition of RayThera Inc., a San Diego-based small-molecule immunology company, for up to $1 billion. This deal adds multiple anti-inflammatory assets to Biogen's pipeline, with the lead program having entered Phase I development in July 2026. This acquisition is Biogen's …

Biogen completes acquisition of RayThera, advancing immunology pipeline with Phase 1 lead program

Biogen has finalized its acquisition of RayThera Inc., a biotech company specializing in small-molecule therapies for immunology. This acquisition strengthens Biogen's immunology portfolio by adding multiple assets, with RayThera's lead program having entered Phase 1 clinical development in July 2026. The deal underscores Biogen's …

Press Release: Biogen Completes Acquisition of RayThera Inc.

Biogen has successfully completed its acquisition of RayThera Inc., a biotechnology company specializing in novel oncology treatments. This strategic acquisition aims to expand Biogen's pipeline in oncology and leverage RayThera's innovative research. The integration of RayThera's assets is expected to strengthen Biogen's position in …

Biogen completes acquisition of immunology firm RayThera By Investing.com

Biogen Inc. has completed its acquisition of RayThera Inc., an immunology-focused biotechnology company. This acquisition expands Biogen's immunology portfolio with multiple small-molecule assets targeting immune-mediated conditions, including a lead program that entered Phase 1 development in July 2026. The financial terms of the transaction …

Biogen's RayThera Deal Adds a Phase 1 Immunology Program

Biogen (Nasdaq: BIIB) has announced the completion of its acquisition of RayThera Inc., a private biotechnology company specializing in small-molecule immunology therapies. This acquisition enhances Biogen's immunology portfolio by introducing multiple assets, including a lead program that entered Phase 1 development in July 2026. …

Biogen Completes Acquisition of RayThera Inc.

CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology. The acquisition strengthens Biogen’s growing immunology portfolio, adding …

FMR LLC discloses 12.4% Biogen Inc (BIIB) stake totaling 18.29M shares

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 18,294,523.51 shares of Biogen Inc. (BIIB) common stock, which represents a 12.4% stake in the company. FMR LLC holds sole voting power over 16,623,432.57 shares and sole dispositive power over all 18.29 …

Biogen Inc. completed the acquisition of RayThera, Inc. from Foresite Capital Management, LLC, OrbiMed Advisors LLC, TTM Capital and others.

Biogen Inc. has completed the acquisition of RayThera, Inc. for a total consideration of $1 billion. The deal includes an upfront cash payment of $225 million and an additional $775 million contingent on future clinical and regulatory milestones. This acquisition, which excludes certain preclinical …

Biogen Inc (BIIB) Director Lloyd Minor Sells 1,186 Shares

Biogen Inc. Director Lloyd Minor sold 1,186 shares of the company's stock on August 4, 2026, bringing his direct ownership to 2,689 shares. This sale aligns with a broader trend of insider selling at Biogen, with 4 insider sells versus 1 insider buy over …

Biogen Stock: How To Find & Own America's Greatest Opportunities

Biogen is one of the oldest and most venerable biotechs. For a time in the late 1990s, Biogen's share price grew ninefold. Continue Reading

new drugs are rewriting Biogen’s story - News Freedom Broker

Freedom Broker analysts have reaffirmed their "Buy" rating on Biogen Inc. (BIIB) and increased the target price from $245 to $255, citing the company's successful diversification into new drug portfolios. The acquisition of Apellis Pharmaceuticals has been a turning point, with innovative product revenues …

Lloyd Minor (BIIB) files Form 144 for 593-share NASDAQ stock sale

Lloyd Minor, an insider at Biogen Inc. (BIIB), has filed a Form 144 indicating a planned or recent sale of 593 shares of company common stock. These shares were acquired on June 9, 2026, through restricted stock vesting as compensation. The filing also reports …

Form 144 BIOGEN INC. For: 3 August By Investing.com

This article from Investing.com is a brief announcement regarding a Form 144 filing for BIOGEN INC. on August 3rd. It provides no further details about the filing, serving primarily as a notification of its existence. The article also includes various market data, news headlines, …

BIOGEN INC. SEC Filing (Aug 3, 2026)

This SEC filing for Biogen Inc. (BIIB) is a Form 144, indicating a proposed sale of securities under Rule 144. The filing, dated August 3, 2026, details a restricted stock vesting for 593 shares of common stock, with an aggregate market value of $120,580.62, …

BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook

BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook Biotech company Biogen (NASDAQ:BIIB) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was …

Biogen Inc. stock underperforms Friday when compared to competitors

Shares of Biogen Inc. (BIIB) fell 2.40% on Friday, closing at $202.95, despite an overall positive trading session for the broader market. Both the S&P 500 Index and the Dow Jones Industrial Average saw gains. This marks the second consecutive day of losses for …

Biogen stock price target raised to $251 by H.C. Wainwright

H.C. Wainwright raised its price target on Biogen Inc. (NASDAQ:BIIB) to $251 from $237, maintaining a Buy rating, as the company prepares to release results from its lupus drug trials. The firm anticipates a low-to-high-teens SRI-4 separation in the upcoming Phase 3 TOPAZ studies. …